Luca Maini
@luca_maini
Followers
500
Following
162
Media
4
Statuses
155
Assistant Professor of Health Care Policy at @HMSHCP. I study competition and regulation in pharmaceutical markets.
Cambridge, MA
Joined May 2012
Congratulations to Josh Feng, Emma Dean, and Luca Maini on being selected for the 2025 cohort of #NIHCM Research Grantees! Read more in the release: https://t.co/h3Vy1cluiB | #NIHCMGrants2025
0
3
1
This year's Econ job market has, by all accounts, been brutal. If you're still not sure what you're doing next year, applying for external funding to continue your work is a great way to buy yourself time & options. It's a way to "build your own post-doc." Check out AV's open
One month left until letters of interest are due for our most recent RFPs to fund RCTs and quasi experiments of social policies and programs. Learn more about what we’re looking for here 👇
2
25
116
Postdoc alert! The deadline for the position at @HMSHCP is in a little over two weeks. If you are on the econ/health policy market and are interested in pharma, please consider applying!
0
2
1
Many industries where the government is a major regulator, purchaser, or supplier suffer from severe worker shortages (e.g., healthcare, transportation, education, public safety). A quick thread on our new @restatjournal showing how government payment incentives can help: 1/N
Payment incentives alleviate worker shortages at nursing homes. Just Accepted new paper by Ashvin D. Gandhi (@ashdgandhi), Andrew Olenski (@andrewolenski), Krista Ruffini (@KristaRuffini), and Karen Shen
2
24
69
I have terrible news. I took a sneak peek at current submission numbers for ASHEcon and the Prescription Drugs area is not number one. We're not even on the podium. Are we gonna let Health Systems and Health Care Financing win?
🔥 Deadline extended: Dec. 18, 2024 at 11:59 PM PST Submit your abstracts for the 14th ASHEcon Conference 👉 https://t.co/Wyt6SnT6WE The conference will be held June 22-25, 2025 at the Grand Hyatt Nashville in Nashville, TN. We hope to see you there!
0
2
6
There's still time:) Check out the single abstract listing ( https://t.co/7Fviof703P), or email me if you need papers to round out a session on prescription drugs!
0
0
1
Calling all PhD students interested in innovation -- Submit your work to the 8th Annual Wharton Innovation Doctoral Symposium; highly recommended! https://t.co/oibzYyab9i
0
13
39
Glad to serve the new "Innovation & Digitization" area.🚀 Please send in all your relevant papers! The more submissions an area receives, the more we accept. Individual abstracts and organized sessions are all welcome! Single abstract listing ( https://t.co/cMBj1yMuoR) / email me!
One week left to submit your abstracts for the 14th ASHEcon Conference! ⏰ Deadline: Dec. 11, 2024 at 11:59 PM PST Submit here 👉 https://t.co/Wyt6SnT6WE The conference will be held June 22-25, 2025 at the Grand Hyatt Nashville in Nashville, TN. We hope to see you there!
0
2
11
I'm the chair of the prescription drug area this year. Please send in all your pharma papers! The more submissions an area receives, the more we accept. If you need help putting together a session, check the single abstract listing (link at https://t.co/7Fviof703P) or email me!
One week left to submit your abstracts for the 14th ASHEcon Conference! ⏰ Deadline: Dec. 11, 2024 at 11:59 PM PST Submit here 👉 https://t.co/Wyt6SnT6WE The conference will be held June 22-25, 2025 at the Grand Hyatt Nashville in Nashville, TN. We hope to see you there!
0
4
14
📢hi #econtwitter - if you are still here, I am looking for ONE paper to complete an organized session for #ASHEcon2025 on the topics of ~PE, corporate ownership, vertical integration, mergers & acquisitions in health care, etc.
6
14
20
🚨 What happens when the gov't cuts prices on medical technologies? New research (w/ @YunanJi) finds a 61% price cut led to: 75% drop in innovation (may fully offset savings) 49% fewer new firms 28% more production moved overseas 3x repair/replacement rate 🧵(1/n)
15
165
586
Third takeaway: most other acquisitions seem to have no obvious effect on prices or coverage (caveat: drug prices move a lot, so it’s hard to detect these effects with precision)
0
0
0
Second takeaway: acquisitions that are not disclosed to the FTC are followed by massive increases in price, and large declines in formulary coverage (caveat: there are not that many of them!)
2
0
1
First takeaway: there is a lot of M&A! One third of all branded drugs are acquired prior to patent expiration. Most of them are acquired by companies that have NO other drug with a similar indication.
1
0
0
Research update: we have a new version of our pharma M&A paper! AND, we posted the data we collected on m&a deals. Links below, main takeaways in thread. Paper summary: https://t.co/EKZykdsXHU Full draft: https://t.co/UjkOyIP1Dk Data:
lucamaini.com
1
17
59
I have a few overdue research updates I will post about in the next week or two. But first, our department @HMSHCP is hiring a postdoc to work with me on pharma topics. Posting here: https://t.co/ejzX1AXxrn Please circulate, and feel free to reach out with any questions!
2
6
6
New paper out, led by @pragyakakani! Check out the podcast at the end of the thread--just the right length for your work commute
Proud to share our new work in @Health_Affairs. We show Medicare Part D’s special treatment of protected class drugs, which plans are prohibited from excluding, is associated with lower negotiated drug rebates – likely meaning higher costs for taxpayers.
0
1
13
Is it weird that the FTC complaint against PBMs is the most riveting evening read I have done in years?
0
0
6
People stick to their initial drug choices even when new treatments become available. In the March 2024 issue of REStat by Josh Feng, @joshfeng89.
direct.mit.edu
Abstract. I use temporal discontinuities in choice sets to identify history dependence in drug demand, finding large and long-term effects. Quasi-randomly assigning a patient to a drug today increa...
0
5
20
New paper coming out with @joshfeng89! Read Josh’s thread if you are interested in drug price negotiations!
Thread on a forthcoming article with @luca_maini: What is the impact of pharmacy benefit managers on prescription drug prices and drug spending? (1/10) https://t.co/4vhVc07zEm
0
0
6